Clinical Trial Update: A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men [Phase 1]

View source ↗

Summary

Phase 1 study evaluating whether rifampin, a liver enzyme inducer, alters the metabolism of enzalutamide in men to assess potential drug-drug interactions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Drug-Drug Interaction (DDI), Healthy Subjects | Phase 1 | Status: COMPLETED